Bao Le

General Counsel at SENSEI BIOTHERAPEUTICS, INC.

Health Technology

Profile

Bao Le is currently the Vice President of Regulatory Affairs at Sensei Biotherapeutics, Inc. She started this job in 2021.
Previously, she worked as the Vice President and Head of Global Regulatory Affairs at enGene, Inc.

Bao Le active positions

Companies	Position	Start
SENSEI BIOTHERAPEUTICS, INC.	General Counsel	01/06/2021

All active positions of Bao Le

Former positions of Bao Le

Companies	Position	End
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	General Counsel	-

See the detail of Bao Le's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Bao Le's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SENSEI BIOTHERAPEUTICS, INC.	Health Technology

Private companies	1
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Health Technology